Currently, there are approved medications, especially those that act as GLP-1 and/or GIP agonists, that achieve significant body weight reduction (more than 10%), compared to placebo
Glutathione has been shown to reduce hyperpigmentation by inhibiting the tyrosinase enzyme, as well as switching melanogenesis (melanin production) from the darker eumelanin to the lighter phaeomelanin
Evidence type: Human RCT | Observational | Animal
Patients with pre-existing liver conditions should discuss appropriate monitoring strategies with their healthcare provider
doi: 10.5114/ceji.2020.103422 66 PrakashAGoaKL
Retatrutide is dosed once weekly by subcutaneous injection, titrated in 4-week steps from a 2 mg start through 4, 8 and 12 mg, with 12 mg being the maximum dose tested in the 2023 NEJM Phase 2 trial (24.2% mean weight loss at 48 weeks) [5][2]